Andrew F. Alexis, MD, MPH

Andrew Alexis, MD, MPH, discusses how, in creating individualized treatment plans for vitiligo, clinicians must carefully consider the distinct challenges and response patterns associated with segmental vs nonsegmental forms, as segmental vitiligo tends to be more stable after initial progression but often more resistant to treatment, while nonsegmental vitiligo typically shows a more unpredictable course requiring ongoing management strategies.

The panelist discusses the primary challenges in vitiligo repigmentation, including maintaining patient compliance through lengthy treatment courses and managing expectations around partial repigmentation outcomes, which require careful monitoring and ongoing patient education about realistic goals while assessing success through standardized documentation of even minimal improvements to inform treatment adjustments.

Andrew Alexis, MD, MPH, discusses how holistic management of vitiligo requires addressing both the physical and psychological impact through empathetic counseling and support groups while setting realistic treatment expectations and timelines with patients through clear communication about repigmentation goals, potential outcomes, and available therapeutic options.

Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.

An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.

Andrew Alexis, MD, MPH, presents the case of a 60-year-old man with a 5-year history of vitiligo who received topical ruxolitinib 1.5% cream and achieved gradual repigmentation over a six-month period.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, talk about how clinical approaches and understanding of risk/benefit profiles are evolving in light of the emerging long-term data.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the impact of the open-label extension data on the current atopic dermatitis landscape.

Thought leaders discuss the importance of rapid onset of action in atopic dermatitis care amid the backdrop of compelling 4-year efficacy and safety data for dupilumab.

Continuing their discussion about efficacy, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review long-term results on pruritus. Additionally, they explore data for patients who switched from weekly to every-other-week dupilumab treatment.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, discuss the relevance of the 4-year efficacy data for dupilumab in adults with moderate to severe atopic dermatitis, with a focus on IGA and EASI scores.

Continuing their discussion about safety, Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, take a closer look at conjunctivitis data from the long-term use of dupilumab

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the design of the LIBERTY-AD open-label extension trial and share clinical context regarding safety findings.

Thought leaders share strategies for talking to patients about the importance of treatment adherence in the long-term management of atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, evaluate the effect of the rapidly changing therapeutic landscape in atopic dermatitis.

Andrew F. Alexis, MD, MPH, and Benjamin N. Lockshin, MD, review the burden of atopic dermatitis and discuss how they talk to patients about the impact their disease has on their lives.